Healthtech
The latest data and global trends in health and healthtech startups, venture capital, exits and innovation.
Put your brand in front of the readers of this guide.
Sponsor this guide →Annual venture capital
Quarterly venture capital
The structure of health investing
Biotech and therapeutics
Drug discovery and development, oncology, genomics and precision medicine. The most capital-intensive layer, with long, binary, clinically-gated timelines and large milestone-driven rounds. AI-enabled drug discovery has pulled new venture capital into this layer, compressing parts of the early pipeline.
Medtech and diagnostics
Medical devices, surgical robotics, diagnostics and medical imaging, and the wearables that increasingly feed clinical data back into care. Hardware and regulatory pathways shape the funding profile; rounds are smaller than in therapeutics but the path to revenue is shorter.
Digital health and care delivery
Telehealth, mental health, women's health, elderly care, and the payer and insurance technology that pays for it all. This is the most software-like layer, with higher deal volume, smaller rounds and where much of the recent company formation in health sits.
Health venture capital raised by stage
Health venture capital raised by stage, quarterly
Startup
Breakout
Scaleup
Top investors
Most active Health investors
| # | Investor | Type | Investments | Portfolio | HQ |
|---|---|---|---|---|---|
| 1 | Accelerator | 1,104 | 6,920 | Mountain View, United States | |
| 2 | Private equity | 586 | 391 | New York City, United States | |
| 3 | Venture capital | 581 | 1,250 | Princeton, United States | |
| 4 | Venture capital | 543 | 1,182 | Menlo Park, United States | |
| 5 | Accelerator | 479 | 428 | Munich, Germany | |
| 6 | Venture capital | 418 | 309 | Boston, United States | |
| 7 | Investment fund | 377 | 1,352 | Maisons-Alfort, France | |
| 8 | Venture capital | 369 | 836 | Menlo Park, United States | |
| 9 | Venture capital | 368 | 249 | Chicago, United States | |
| 10 | Accelerator | 353 | 1,210 | Canberra, Australia |
Source: Dealroom.co
Top companies
Top funded
All-time total funding (includes non-VC sources)
- 1
Moderna TherapeuticsCambridge, United States$6.7B - 2
VerilySan Francisco, United States$3.8B - 3
Altos LabsLos Altos, United States$3.3B - 4
Isomorphic LabsLondon, United Kingdom$2.7B - 5
Devoted HealthWaltham, United States$2.3B - 6
ResilienceSan Diego, United States$2.0B - 7
EQRxCambridge, United States$1.9B - 8
Radiology PartnersEl Segundo, United States$1.9B - 9
JD HealthDongcheng District, China$1.8B - 10
GRAILMenlo Park, United States$1.8B
Hottest (Dealroom Signal)
Ranked by Dealroom's growth indicator
- 1
ŌURAOulu, Finland98 - 2
AbridgePittsburgh, United States98 - 3
Recursion PharmaSalt Lake City, United States97 - 4
PagerNew York City, United States97 - 5
Vera TherapeuticsBrisbane, United States97 - 6
PolicyBazaarGurugram, India97 - 7
NablaParis, France97 - 8
Vivan TherapeuticsLondon, United Kingdom97 - 9
WhoopBoston, United States97 - 10
Hippocratic AIPalo Alto, United States96
Source: Dealroom.co
How Health funding is distributed geographically
The United States
The largest single source of health venture capital, anchored by the Bay Area and New York alongside Boston, Seattle, Los Angeles and a long tail of smaller hubs. Deep late-stage capital and the biggest acquirers keep the US share of the global total well ahead of any other region.
Europe
London, Paris, Berlin, the Nordics and a dense network of smaller ecosystems. Europe's health funding has grown faster than the US in percentage terms but from a smaller base, and supportive policy in several sub-sectors has helped specific hubs punch above their weight.
Asia and the rest of the world
China, India, Singapore and Israel contribute meaningfully, though disclosed venture rounds often understate the capital deployed through state-backed and strategic investors. Coverage here is partial, and headline totals should be read as a floor rather than a full picture.
Top hubs
Top metro regions
Health startups venture capital by metro · Last 12 months to end of Q1 2026
- 1🇺🇸Bay AreaUnited States$13.2B
- 2🇺🇸BostonUnited States$8.3B
- 3🇺🇸New York CityUnited States$5.8B
- 4🇺🇸San DiegoUnited States$2.2B
- 5🇺🇸Los AngelesUnited States$2.1B
- 6🇺🇸AustinUnited States$1.6B
- 7🇺🇸MiamiUnited States$1.4B
- 8🇬🇧LondonUnited Kingdom$1.2B
- 9🇨🇳ShanghaiChina$1.2B
- 10🇰🇷SeoulSouth Korea$1.1B
Top metro regions
Health startups venture capital by metro · Full year 2025
- 1🇺🇸Bay AreaUnited States$12.1B
- 2🇺🇸BostonUnited States$8.7B
- 3🇺🇸New York CityUnited States$5.8B
- 4🇬🇧LondonUnited Kingdom$2.3B
- 5🇺🇸San DiegoUnited States$2.1B
- 6🇺🇸Los AngelesUnited States$1.9B
- 7🇺🇸AustinUnited States$1.6B
- 8🇺🇸Research TriangleUnited States$1.4B
- 9🇰🇷SeoulSouth Korea$1.1B
- 10🇺🇸SeattleUnited States$986M
Top metro regions
Health startups venture capital by metro · Q1 2026
- 1🇺🇸Bay AreaUnited States$4.2B
- 2🇺🇸BostonUnited States$2.2B
- 3🇺🇸New York CityUnited States$1.6B
- 4🇺🇸MiamiUnited States$621M
- 5🇨🇳ShanghaiChina$600M
- 6🇺🇸Los AngelesUnited States$573M
- 7🇺🇸PhiladelphiaUnited States$530M
- 8🇺🇸San DiegoUnited States$387M
- 9🇫🇷ParisFrance$379M
- 10🇺🇸AustinUnited States$320M
Top metro regions
Health startups enterprise value by metro
- 1🇺🇸Bay AreaUnited States$891.0B
- 2🇺🇸BostonUnited States$635.7B
- 3🇺🇸New York CityUnited States$274.5B
- 4🇺🇸San DiegoUnited States$226.2B
- 5🇨🇳ShanghaiChina$121.7B
- 6🇺🇸Los AngelesUnited States$111.7B
- 7🇨🇳BeijingChina$94.4B
- 8🇺🇸AustinUnited States$75.2B
- 9🇬🇧LondonUnited Kingdom$63.1B
- 10🇰🇷SeoulSouth Korea$63.0B
Top metro regions
Health startups unicorns by metro
- 1🇺🇸Bay AreaUnited States134
- 2🇺🇸BostonUnited States95
- 3🇺🇸New York CityUnited States70
- 4🇺🇸San DiegoUnited States41
- 5🇺🇸Los AngelesUnited States26
- 6🇬🇧LondonUnited Kingdom18
- 7🇨🇳ShanghaiChina15
- 8🇺🇸SeattleUnited States14
- 9🇺🇸AustinUnited States13
- 10🇺🇸MiamiUnited States11
Top metro regions
Health VC growth by metro · Last 12 months to end of Q1 2026 vs 2025
- 1🇺🇸MadisonUnited States+107%
- 2🇨🇭ZurichSwitzerland+78%
- 3🇺🇸PhiladelphiaUnited States+73%
- 4🇳🇱UtrechtNetherlands+69%
- 5🇺🇸BoulderUnited States+64%
- 6🇺🇸MiamiUnited States+54%
- 7🇺🇸HoustonUnited States+43%
- 8🇨🇳ShanghaiChina+38%
- 9🇮🇳DelhiIndia+25%
- 10🇺🇸AtlantaUnited States+22%
Top metro regions
Health VC concentration by metro · Last 12 months to end of Q1 2026
- 1🇫🇮OuluFinland9.27×
- 2🇺🇸Minneapolis–Saint PaulUnited States8.48×
- 3🇺🇸BostonUnited States6.02×
- 4🇺🇸Research TriangleUnited States5.92×
- 5🇨🇭ZurichSwitzerland4.65×
- 6🇩🇰CopenhagenDenmark4.64×
- 7🇨🇭LausanneSwitzerland4.44×
- 8🇺🇸MiamiUnited States4.00×
- 9🇺🇸NashvilleUnited States3.94×
- 10🇪🇸BarcelonaSpain3.87×
Top metro regions
Health unicorn concentration by metro · by HQ
- 1🇨🇭BaselSwitzerland4.54×
- 2🇺🇸New HavenUnited States4.53×
- 3🇬🇧OxfordUnited Kingdom3.89×
- 4🇺🇸NashvilleUnited States3.72×
- 5🇺🇸San DiegoUnited States3.45×
- 6🇮🇱HaifaIsrael2.71×
- 7🇩🇪FrankfurtGermany2.59×
- 8🇺🇸BostonUnited States2.49×
- 9🇺🇸Research TriangleUnited States2.16×
- 10🇺🇸Minneapolis–Saint PaulUnited States2.06×
Health on the map
Notable rounds
Biggest Health rounds · Last 12 months to end of Q1 2026 (Top 15 rounds)
| Date | Company | Amount | Round | Lead investors |
|---|---|---|---|---|
| Jan 2026 | Retro Biosciences | $1.0B | SERIES A | Sam Altman, Sandro Salsano |
| Sep 2025 | ŌURA | $900M | SERIES E | Fidelity Investments |
| Mar 2026 | Earendil Labs | $745M | LATE VC | Sanofi, Luminous Ventures |
| Jun 2025 | Neuralink | $650M | SERIES E | Lightspeed Venture Partners, Founders Fund |
| Oct 2025 | Kailera Therapeutics | $600M | SERIES B | Bain Capital Private Equity |
| Mar 2026 | Whoop | $575M | SERIES G | Collaborative Fund |
| Aug 2025 | Sharps Technology | $400M | PRIVATE PLACEMENT VC | Pantera Capital, ParaFi Capital |
| Jul 2025 | TCG Labs Soleil | $400M | PRIVATE PLACEMENT VC | , |
| Jul 2025 | MapLight Therapeutics | $372M | SERIES D | Goldman Sachs Asset Management, Forbion Capital Partners |
| Oct 2025 | Tubulis | $339M | SERIES C | Venrock |
| Sep 2025 | Kriya Therapeutics | $320M | SERIES D | Patient Square Capital, Premji Invest |
| Jan 2026 | Parabilis Medicines | $305M | SERIES F | Janus Henderson Investors, Fidelity Investments |
| Mar 2026 | Verily | $300M | LATE VC | Series X Capital |
| Sep 2025 | Strive Health | $300M | SERIES D | NEA |
| Jun 2025 | Abridge | $300M | SERIES E | Andreessen Horowitz |
Biggest Health rounds · Full year 2025 (Top 15 rounds)
| Date | Company | Amount | Round | Lead investors |
|---|---|---|---|---|
| Sep 2025 | ŌURA | $900M | SERIES E | Fidelity Investments |
| Jun 2025 | Neuralink | $650M | SERIES E | ARK Invest, Qatar Investment Authority |
| Oct 2025 | Kailera Therapeutics | $600M | SERIES B | Bain Capital Private Equity |
| Mar 2025 | Isomorphic Labs | $600M | LATE VC | Thrive Capital |
| Jan 2025 | Immunovant | $450M | PRIVATE PLACEMENT VC | , |
| Jan 2025 | Verdiva Bio | $411M | SERIES A | General Atlantic, Forbion Capital Partners |
| Aug 2025 | Sharps Technology | $400M | PRIVATE PLACEMENT VC | ParaFi Capital, Pantera Capital |
| Jul 2025 | TCG Labs Soleil | $400M | PRIVATE PLACEMENT VC | , |
| Jul 2025 | MapLight Therapeutics | $372M | SERIES D | Forbion Capital Partners, Goldman Sachs Asset Management |
| Feb 2025 | Eikon Therapeutics | $351M | SERIES D | E15 VC, The Column Group |
| Oct 2025 | Tubulis | $339M | SERIES C | Venrock |
| Sep 2025 | Kriya Therapeutics | $320M | SERIES D | Premji Invest, Patient Square Capital |
| Jan 2025 | Truveta | $320M | LATE VC | Advocate Health, Henry Ford Health System |
| Sep 2025 | Strive Health | $300M | SERIES D | NEA |
| Jun 2025 | Abridge | $300M | SERIES E | Andreessen Horowitz |
Biggest Health rounds · Q1 2026 (Top 15 rounds)
| Date | Company | Amount | Round | Lead investors |
|---|---|---|---|---|
| Jan 2026 | Retro Biosciences | $1.0B | SERIES A | Sandro Salsano, Sam Altman |
| Mar 2026 | Earendil Labs | $745M | LATE VC | Dimension Capital, INCE Capital |
| Mar 2026 | Whoop | $575M | SERIES G | Collaborative Fund |
| Jan 2026 | Parabilis Medicines | $305M | SERIES F | Janus Henderson Investors, RA Capital Management |
| Mar 2026 | Verily | $300M | LATE VC | Series X Capital |
| Jan 2026 | CORXEL Pharmaceuticals | $287M | SERIES D | TCGX, HBM Healthcare Investments |
| Jan 2026 | Qiangnao Technology | $286M | LATE VC | , |
| Jan 2026 | Cellares | $277M | SERIES D | Eclipse Ventures, BlackRock |
| Jan 2026 | Merge Labs | $252M | SEED | OpenAI, Bain Capital |
| Jan 2026 | Varda Space | $250M | SERIES D | , |
| Mar 2026 | Findhelp | $250M | GROWTH EQUITY VC | TPG |
| Jan 2026 | Mirador Therapeutics | $250M | SERIES B | OrbiMed, ARCH Venture Partners |
| Jan 2026 | OpenEvidence | $250M | SERIES D | DST Global, Thrive Capital |
| Mar 2026 | Solid Biosciences | $240M | PRIVATE PLACEMENT VC | Vestal Point Capital, Perceptive Advisors |
| Feb 2026 | SHINE Technologies | $240M | LATE VC | NantCell | Nantworks |
Source: Dealroom.co · Updated 17 Jun 2026
What's heating up inside Health
Source: Dealroom.co · Updated 17 Jun 2026
Unicorns & exits
The academic flywheel
Health startup IP & patents
Explore the health landscape
Want to go deeper?
Dealroom tracks Health startups and the entire global startup economy in real time. Book a demo to explore the live data behind this guide and build your own views.
Book a demo

















